Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:

NCT ID: NCT03205111 Not yet recruiting - Uterine Bleeding Clinical Trials

Role of Office Hysteroscope in Premenopausal Uterine Bleeding

Start date: July 2017
Phase: N/A
Study type: Observational

The aim of this study is to photographically characterize the endometrium in patients presenting with abnormal uterine bleeding at age group from 20 to 45 years old. and compare dilatation and curettage with hysteroscopy in obtaining an accurate diagnosis of the etiology of abnormal uterine bleeding.

NCT ID: NCT03203980 Not yet recruiting - Bleeding Clinical Trials

Bleeding Events After Triple Antithrombotic Therapy Initiation.

HEMOTRI
Start date: July 15, 2017
Phase: N/A
Study type: Observational

The optimal antithrombotic therapy for patients requiring anticoagulation after coronary stenting is unknown. Double platelets suppressive agents combined with oral anticoagulation (triple antithrombotic therapy) remains the Gold standard. Our study aims at studying bleeding events occurring until 6 months after the initiation of triple antithrombotic therapy.

NCT ID: NCT03166683 Not yet recruiting - Surgery Clinical Trials

Standard of Care Versus Hemopatch® During Liver Resection

IBERLIVER
Start date: December 2017
Phase: N/A
Study type: Interventional

This multicentre prospective and randomized study aims to compare the sealant effect after surgical liver resection of a new collagen - polyethylene glycol hemostatic / sealant patch (Hemopatch) vs standard of care.

NCT ID: NCT03130127 Not yet recruiting - Liver Cirrhosis Clinical Trials

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Terlipressin is the mainstay drug for the treatment of acute variceal bleeding in liver cirrhosis. According to the drug instructions, intravenous bolus infusion is the standard approach of terlipressin. It remains unclear about whether or not continuous infusion of terlipressin should be considered.

NCT ID: NCT03094975 Not yet recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

A Multicenter Registry Study of Aneurysmal SAH

Start date: July 1, 2017
Phase: N/A
Study type: Observational

Firstly, this study aims at clarifying the current situation of Emergency treatment of aneurysmal subarachnoid hemorrhage (SAH) in China, and analyzing the influencing factors contributing to transport delay, so as to improve the efficiency of emergency treatment; Secondly, comparison and analysis of different surgical treatment of aneurysmal SAH would be undertook, so as to improve the diagnosis and treatment of aneurysmal SAH.

NCT ID: NCT03011866 Not yet recruiting - Spinal Stenosis Clinical Trials

Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries

TARGETS
Start date: February 2017
Phase: N/A
Study type: Interventional

Multilevel decompression and bone graft fusion is a most effective measure for treating degenerative lumbar spinal diseases. Yet, the surgery is commonly associated with large amount of perioperative blood loss and high demand for homologous blood transfusion. Tranexamic acid (TXA) has been proved as efficient in reducing the gross blood loss in various kinds of surgeries. However, high quality evidence of its efficacy and safety is still lacking in lumbar spinal surgeries. Besides, systemic use of TXA carries the risks of thromboembolic complications such as deep venous thrombosis and pulmonary embolism, thus the optimal drug delivery route of TXA remains undetermined. The aim of this study is to test the non-inferiority of topical TXA application to its intravenous use in multilevel decompression and bone graft fusion surgeries. A prospective, randomized, double-blind, head-to-head comparison study design will be adopted.

NCT ID: NCT03010709 Not yet recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Multimodality Monitoring Directed Management of Aneurysmal Subarachnoid Haemorrhage

MMMSAH
Start date: February 2017
Phase: N/A
Study type: Observational

Aneurysmal subarachnoid haemorrhage (aSAH) affects up to 10,000 individuals per year in the UK. It accounts for ~5% of strokes, but is responsible for about 25% quality-adjusted life years (QALYs) lost due to stroke. Although early repair of ruptured aneurysms and aggressive postoperative management has improved overall outcomes, it remains a devastating disease with mortality approaching 50%. Survivors are left with neurological injuries that range from subtle cognitive deficit to disabling cerebral infarctions, less than 60% them returning to functional independence. SAH triggers a series of pathological processes resulting in neuronal damage and consequent neurological deficit termed early brain injury (EBI). Many of the patients who survive the initial bleed, deteriorate days later from delayed ischaemic neurological deficit (DIND), which causes poor outcome or death in up to 30% of patients with SAH. Both of these pathological processes are still poorly understood which limits the number of treatment options. DIND is treated with blood pressure augmentation to ensure adequate blood flow in the brain. In awake patients, response can be easily and accurately assessed by performing a thorough neurological examination. In patients whose clinical condition demands sedation, intubation and ventilation, assessing response to treatment using the neurological examination is virtually impossible. Multimodality monitoring (MM), primarily microdialysis and brain tissue oxygen tension with catheters inserted into the relevant parts of the brain offer direct assessment of both delivery and utilisation of metabolic substrates at the cellular level. These can be used for early detection of DIND as well as monitoring during blood pressure augmentation. The aim of this study is to establish and validate a clinical protocol for MM derived management of SAH patients, to determine optimal therapies for correcting abnormalities in brain metabolism and explore the relationship between MD and other monitoring modalities.

NCT ID: NCT02939092 Not yet recruiting - Gingival Bleeding Clinical Trials

The Effect of Mouthwash Containing Pomegranate Peel Extract and Chlorhexidine Mouthwash on Bleeding on Brushing

Start date: January 2018
Phase: N/A
Study type: Interventional

To evaluate the clinical effectiveness of mouthwash containing pomegranate peel extract and chlorhexidine mouthwash on bleeding on brushing and counting of streptococcus mutans among a group of Egyptian children with permanent dentition.

NCT ID: NCT02936661 Not yet recruiting - Clinical trials for Postpartum Hemorrhage, Cesarean Section

Tranexamic Acid for Preventing Postpartum Hemorrhage After Cesarean Section

Start date: April 2017
Phase: Phase 4
Study type: Interventional

It is a multicenter randomized, double-blind and placebo-controlled trial. Totally 6500 women to delivery by cesarean section will be recruited in this study. In addition to routinely oxytocin, the women in study group will receive TXA 1 g in 2 minutes after they delivered their babies, and those in control group will receive placebo. The incidence of postpartum hemorrhage, the amount of bleeding, as well as the side effects will be observed.

NCT ID: NCT02915380 Not yet recruiting - Clinical trials for Subarachnoid Haemorrhage From Cerebral Aneurism Rupture

Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage

TIRASH
Start date: January 2017
Phase: N/A
Study type: Observational

Recently, the occurrence and potential impact of pituitary dysfunction after aSAH has gained increasing interest. Several studies have demonstrated pituitary dysfunction after SAH suggesting that pituitary dysfunction may be a contributing factor for residual symptoms after SAH. This is an observational multicentric study aimed to test the prevalence of thyroid abnormalities, other neuroendocrinological dysfunction and their influence on outcome of patients affected by aSAH.